UBS Group AG Registered Ordinary Shares (UBS)
38.00
+0.00 (0.00%)
NYSE · Last Trade: Jul 30th, 5:38 AM EDT
Detailed Quote
| Previous Close | 38.00 |
|---|---|
| Open | - |
| Bid | 38.64 |
| Ask | 38.68 |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.75 - 38.42 |
| Volume | 55,407 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | 0.7000 (1.84%) |
| 1 Month Average Volume | 2,171,454 |
Chart
About UBS Group AG Registered Ordinary Shares (UBS)
UBS Group AG is a global financial services company providing a wide range of financial services to clients, including wealth management, investment banking, and asset management. The firm caters to private, corporate, and institutional clients, delivering tailored financial solutions and expertise across various sectors and regions. UBS is known for its strong focus on sustainable finance and innovation, striving to create long-term value for its stakeholders while maintaining a commitment to corporate responsibility and ethical practices in the financial industry. Read More
News & Press Releases
Shares of health coverage company Centene (NYSE:CNC)
fell 3.3% in the morning session after JPMorgan cut its price target on the managed care company to $30 from $48. This move by JPMorgan followed Centene's recent second-quarter earnings report, where the company posted a loss of $0.16 per share, missing analyst estimates. The poor results were largely attributed to a significant reduction in the company's net 2025 Marketplace risk adjustment revenue transfer estimate, an issue that first came to light when Centene withdrew its full-year guidance on July 1st. The company's performance prompted a series of downgrades from Wall Street, with firms like UBS, Wells Fargo, and Morgan Stanley also cutting their price targets, signaling widespread concern over the company's ability to restore its earnings trajectory.
Via StockStory · July 29, 2025
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP)
fell 3.3% in the morning session after UBS downgraded the stock to 'Sell' from 'Neutral', sending shares lower. The investment bank expressed concerns that Medpace's near and mid-term financial targets appeared "overly ambitious" given a weak industry environment. UBS noted that meeting its objectives would require record bookings in the second half of the year, which seemed challenging due to several negative factors. These factors included weak biotech capital markets, fewer clinical trial starts, and muted hiring. The downgrade came despite a slight increase in the firm's price target on the stock to $305 from $300. Recent news of significant stock sales by the company's President and CFO also may have contributed to investor concerns.
Via StockStory · July 29, 2025
Crocs Stock Climbs As UBS Lifts Price Target To $110, Retail Maintains Bullish Buzz Despite Tariff Cloudsstocktwits.com
Via Stocktwits · July 28, 2025
Shares of semiconductor packaging and testing company Amkor Technology (NASDAQ:AMKR) jumped 19.3% in the morning session after the company reported strong second-quarter financial results that significantly beat analyst expectations and provided a robust outlook. The semiconductor packaging and test services provider posted earnings per share of $0.22, surpassing the forecasted $0.16. Revenue reached $1.51 billion, which was also ahead of the $1.42 billion consensus estimate. The company noted a 14% sequential increase in sales, with double-digit growth across all its end markets, highlighting strong demand in Artificial Intelligence (AI) and high-performance computing (HPC). In response to the strong quarter and positive guidance, analysts at Needham raised their price target on the stock to $28, while UBS increased its target to $25, with both firms maintaining their Buy ratings.
Via StockStory · July 29, 2025
Circle has minted native USDC on Sei and activated CCTP V2, enabling sub-second, slippage-free stablecoin flows across 13 chains.
Via Stocktwits · July 29, 2025
According to Fiscal.ai data, Wall Street expects the parcel delivery firm to post earnings of $1.57 per share on revenue $20.85 billion for the second quarter.
Via Stocktwits · July 29, 2025
Shares of clothing and footwear retailer Boot Barn (NYSE:BOOT)
jumped 3.1% in the morning session after analysts at JPMorgan Chase & Co. and Piper Sandler raised their price targets on the stock, signaling confidence in the company's outlook.
Via StockStory · July 28, 2025
Shares of footwear conglomerate Wolverine Worldwide (NYSE:WWW)
jumped 3% in the morning session after analyst firm UBS raised its price target on the footwear company to $30 from $22, while maintaining its Buy rating on the stock. The investment firm pointed to expectations of a robust second quarter for the company. This optimism was reportedly fueled by strong momentum from its Saucony brand and solid performance from the Merrell brand. UBS also forecasted that Wolverine would likely exceed consensus earnings per share (EPS) estimates by 4 cents for the quarter.
Via StockStory · July 28, 2025
A UBS-SBI-LINK pilot shows tokenized funds settling cross-chain with instant NAV feeds and atomic cash-and-asset delivery.
Via Stocktwits · July 28, 2025
AMD stock rose Monday on reports that it has increased the price of its high-end AI chip in a show of confidence vs. Nvidia.
Via Investor's Business Daily · July 28, 2025
“Pay with Crypto” enables U.S. merchants to accept payments in over 100 cryptocurrencies via major wallets, including Coinbase and MetaMask.
Via Stocktwits · July 28, 2025
UBS anticipates AMD’s upcoming guidance to exceed market consensus.
Via Stocktwits · July 28, 2025
JPMorgan maintained its ‘Overweight’ rating on the shares, according to TheFly, and said its fieldwork indicates a strong close to the quarter resulting from steady demand.
Via Stocktwits · July 28, 2025
Shares of animal health company Elanco (NYSE:ELAN)
jumped 3% in the pre-market session after the company received approval from the European Commission for its canine dermatitis treatment, Zenrelia.
Via StockStory · July 25, 2025
Shares of specialty construction contractor company EMCOR (NYSE:EME)
jumped 8.7% in the afternoon session after an analyst at UBS raised the company's price target ahead of its upcoming earnings report.
Via StockStory · July 25, 2025
Shares of online marketplace Etsy (NASDAQ:ETSY)
jumped 3.1% in the morning session after the stock hit a new 52-week high of $66.21, fueled by strong recent performance and positive analyst updates. The e-commerce platform's stock had already seen a significant climb, rising 48% over the past couple of months and gaining over 8% in the past week alone.
Via StockStory · July 24, 2025
Shares of auto parts and accessories retailer O’Reilly Automotive (NASDAQ:ORLY) jumped 4.8% in the afternoon session after the company reported strong second-quarter 2025 financial results and raised its full-year outlook. The auto parts retailer announced a 4.1% increase in comparable store sales and an 11% rise in diluted earnings per share to $0.78 for the second quarter. Total revenue for the period grew 6% to $4.53 billion, while net income rose 7% to $669 million. Following the strong performance, O'Reilly raised its full-year 2025 guidance for comparable store sales. The positive report prompted favorable reactions from Wall Street analysts. For instance, UBS raised its price target on the stock to $115, and Wells Fargo increased its target to $105.
Via StockStory · July 24, 2025
Shares of healthcare insurance company Molina Healthcare (NYSE:MOH)
fell 14.4% in the afternoon session after the company reported second-quarter earnings that missed analyst expectations and lowered its full-year financial guidance due to rising medical costs. The health insurer's adjusted earnings per share of $5.48 fell short of the $5.62 analyst estimate, driven by margin pressure from higher-than-expected medical expenses. The company's Medical Care Ratio (MCR), which measures how much premium revenue is spent on medical care, increased to 90.4% from 88.6% in the prior year. Consequently, Molina revised its full-year 2025 adjusted earnings guidance to be no less than $19.00 per diluted share, a reduction from a previously lowered target. The company cited a “challenging medical cost trend environment” for the results, which also included a negative operating cash flow of $112 million for the first half of the year.
Via StockStory · July 24, 2025
The Trump administration's "AI Action Plan" and Google's increased data center spending are likely to buoy Nvidia stock and others.
Via Investor's Business Daily · July 24, 2025
RTX stock is expensive when valued on earnings. Valued on free cash flow... it's even more expensive.
Via The Motley Fool · July 23, 2025
Shares of online dating app Bumble (NASDAQ:BMBL)
jumped 7.8% in the afternoon session after an analyst at UBS raised the price target on the stock and positive sentiment lifted consumer-focused companies. UBS analyst Chris Kuntarich increased the firm's price target on Bumble to $7.50 from $6.00 while maintaining a "Neutral" rating on the shares. The move came amid a broader rally for consumer internet stocks. Market sentiment received a boost after the announcement of a new U.S.-Japan trade deal, which eased investor concerns over international trade disputes by lowering proposed tariffs on certain imports. This development was seen as a positive for the economy, potentially supporting consumer purchasing power. For a company like Bumble, whose revenue depended on users paying for subscriptions and premium features, signs of a confident consumer were a positive indicator.
Via StockStory · July 23, 2025
Microsoft stock has been crowned an AI winner, but it will need to prove its bona fides with its fiscal Q4 report next week.
Via Investor's Business Daily · July 23, 2025
UBS Global Wealth Management US today announced that J. Mills-Pierre III has joined the firm as a Financial Advisor. Mills joins the UBS Manhattan Market, led by Market Executive Kellie Brady, and is based in the firm’s 299 Park Avenue location. He reports to Market Director Neal Cooper and Associate Market Executive Demie Kommatas.
By UBS · Via Business Wire · July 22, 2025